Christina E
14644 Cleanroom #MankindPharma #HealthcareAccess #DiabetesCare #ChronicCare #PharmaIndustry Great Sir if Mankind brings than it will be affordable for many Were proud to support the team at MANKIND PHARMA LTD through 14644 Cleanroom
@Amgen thinks so, releases @Nature phase 1 study of AMG 133 (maridebart cafraglutide) a combination of GIPR antagonist monoclonal anti- body and two GLP-1 agonist peptides Safe, tolerable with dose-dependent weight loss maintained to 150 days go.nature.com/3HUHBjB Join the conversation
These include decreased urination or dark-coloured urine, dry mouth and increased thirst, fatigue or weakness, dizziness when standing, and in severe cases, confusion or altered mental state
Br J Cancer 122 , 18371847 (2020)
Whilst there is no formal contraindication preventing concurrent use, the combination requires careful consideration